AI Article Synopsis
Article Abstract
Neutralizing antibodies targeting the SARS-CoV-2 spike protein have shown a great preventative/therapeutic potential. Here, we report a rapid and efficient strategy for the development and design of SARS-CoV-2 neutralizing humanized nanobody constructs with sub-nanomolar affinities and nanomolar potencies. CryoEM-based structural analysis of the nanobodies in complex with spike revealed two distinct binding modes. The most potent nanobody, RBD-1-2G(NCATS-BL8125), tolerates the N501Y RBD mutation and remains capable of neutralizing the B.1.1.7 (Alpha) variant. Molecular dynamics simulations provide a structural basis for understanding the neutralization process of nanobodies exclusively focused on the spike-ACE2 interface with and without the N501Y mutation on RBD. A primary human airway air-lung interface (ALI) ex vivo model showed that RBD-1-2G-Fc antibody treatment was effective at reducing viral burden following WA1 and B.1.1.7 SARS-CoV-2 infections. Therefore, this presented strategy will serve as a tool to mitigate the threat of emerging SARS-CoV-2 variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365158 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272364 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Second Generation I-Body AD-214 Attenuates Unilateral Ureteral Obstruction (UUO)-Induced Kidney Fibrosis Through Inhibiting Leukocyte Infiltration and Macrophage Migration.
Int J Mol Sci
December 2024
Renal Medicine, Kolling Institute of Medical Research, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Royal North Shore Hospital, St Leonards, NSW 2065, Australia.
Kidney fibrosis is the common pathological pathway in progressive chronic kidney disease (CKD), and current treatments are largely ineffective. The C-X-C chemokine receptor 4 (CXCR4) is crucial to fibrosis development. By using neural cell adhesion molecules as scaffolds with binding loops that mimic the shape of shark antibodies, fully humanized single-domain i-bodies have been developed.
View Article and Find Full Text PDFOn the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality.
Protein Sci
November 2024
Antibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Article Synopsis
- The study focuses on humanizing camelid-derived variable domain heavy chain antibodies (VHHs), addressing challenges like immunogenicity, stability, and affinity reduction, especially through changes in crucial structural regions.
- Researchers systematically exchanged key residues in VHHs targeting NKp30 with human equivalents, then characterized the variants for binding affinity, yield, and purity using methods such as crystal structure determination and AlphaFold2 predictions.
- The study emphasizes the importance of specific sequence motifs and non-canonical disulfide bonds in VHHs, contributing to better understanding their structural determinants to aid in their design and optimization for therapeutic use.
Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor.
J Transl Med
October 2024
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Background: BI 836880 is a humanized bispecific nanobody® that binds to and blocks vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). A comprehensive biomarker and modeling approach is presented here that supported dose finding for BI 836880.
Methods: Two Phase I dose-escalation studies (1336.
An evaluation of mirikizumab for the treatment of ulcerative colitis.
Expert Opin Biol Ther
November 2024
Department of Gastroenterology, St Thomas' Hospital, London, UK.
Article Synopsis
- The treatment of ulcerative colitis (UC) focuses on reducing inflammation, but some patients struggle with current therapies; mirikizumab, an anti-IL-23 antibody, has been approved as a new option for those with moderate to severe UC.
- This review discusses the role of IL-23 in inflammation and details the pharmacokinetics and clinical evidence supporting mirikizumab's efficacy and safety through phase II and III trials.
- Mirikizumab has shown to be more effective than placebo and is a viable option for both new and experienced patients, with flexible dosing options to help those who don't respond well to initial treatment.
AI-based IsAb2.0 for antibody design.
Brief Bioinform
July 2024
Department of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, Pharmacometrics & System Pharmacology PharmacoAnalytics, School of Pharmacy, University of Pittsburgh, 335 Sutherland Drive, Pittsburgh, PA 15261, United States.
Therapeutic antibody design has garnered widespread attention, highlighting its interdisciplinary importance. Advancements in technology emphasize the critical role of designing nanobodies and humanized antibodies in antibody engineering. However, current experimental methods are costly and time-consuming.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!